CM
KNSA icon

Castleark Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Castleark Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.74M Sell
181,512
-10,680
-6% -$473K 0.29% 74
2025
Q4 		$7.93M Buy
192,192
+33,560
+21% +$1.35M 0.23% 99
2025
Q3 		$6.16M Buy
+158,632
New +$5.15M 0.17% 132
2024
Q4 		– Sell
-167,200
Closed -$4.18M – 307
2024
Q3 		$4.18M Buy
+167,200
New +$4.07M 0.17% 134

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Castleark Management's KNSA Position: Q1 2026 in Review

Castleark Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 5.6% in Q1 2026, selling an estimated $473K and leaving 181,512 shares worth $8.74M. The position accounts for 0.29% of the portfolio, ranked #74.

Castleark Management first reported a position in KNSA in Q3 2024 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Castleark Management held 181,512 shares of Kiniksa Pharmaceuticals worth $8.74M as of Q1 2026.
  • Castleark Management sold 10,680 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $473K.
  • Kiniksa Pharmaceuticals made up 0.29% of Castleark Management's portfolio in Q1 2026, its #74 holding.
  • Castleark Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.